203 related articles for article (PubMed ID: 8245897)
41. Oral acyclovir therapy for varicella and zoster infections in pediatric and pregnant patients: a brief review.
Rothe MJ; Feder HM; Grant-Kels JM
Pediatr Dermatol; 1991 Sep; 8(3):236-42, 246-7. PubMed ID: 1745635
[TBL] [Abstract][Full Text] [Related]
42. Polish consensus guidelines on the use of acyclovir in the treatment and prevention of VZV and HSV infections.
Szenborn L; Kraszewska-Głomba B; Jackowska T; Duszczyk E; Majda-Stanisławska E; Marczyńska M; Ołdak E; Pawłowska M; Służewski W; Wysocki J; Stryczyńska-Kazubska J; Kuchar E
J Infect Chemother; 2016 Feb; 22(2):65-71. PubMed ID: 26643900
[TBL] [Abstract][Full Text] [Related]
43. Characterization of acyclovir susceptibility and genetic stability of varicella-zoster viruses isolated during acyclovir therapy.
Ida M; Kageyama S; Sato H; Kamiyama T; Toyomoto T; Ozaki T; Kajita Y; Morohashi M; Shiraki K
J Dermatol Sci; 2000 May; 23(1):63-72. PubMed ID: 10699766
[TBL] [Abstract][Full Text] [Related]
44. Varicella-zoster infection in adults with cystic fibrosis: role of acyclovir.
Ong EL; Mulvenna P; Webb KA
Scand J Infect Dis; 1991; 23(3):283-5. PubMed ID: 1882193
[TBL] [Abstract][Full Text] [Related]
45. [Infections caused by Varicella Zoster virus in children with cancer aged less than 15 years old].
Folatre I; Zolezzi P; Schmidt D; Marín F; Täger M
Rev Med Chil; 2003 Jul; 131(7):759-64. PubMed ID: 14513696
[TBL] [Abstract][Full Text] [Related]
46. Ambulatory management of varicella-zoster virus infection in immunocompromised cancer patients.
Rolston KV; Manzullo E; Elting L; Frisbee-Hume S; Rodriguez S; Rubenstein EB
Support Care Cancer; 1998 Jan; 6(1):57-62. PubMed ID: 9458538
[TBL] [Abstract][Full Text] [Related]
47. Short-time and low-dose intravenous acyclovir therapy in varicella zoster infections with malignant disease in children receiving combined chemotherapy.
Sarialioğlu F; Buyukpamukcu M; Cevik N; Kutluk MT; Akyol H; Kansu E
Pediatr Hematol Oncol; 1986; 3(3):267-71. PubMed ID: 3153239
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathologic understanding and control of varicella-zoster virus infection.
Asano Y
Vaccine; 2008 Nov; 26(50):6487-90. PubMed ID: 18694794
[TBL] [Abstract][Full Text] [Related]
49. Varicella zoster infections in bone marrow transplants.
Feldman S
Recent Results Cancer Res; 1993; 132():175-84. PubMed ID: 8265859
[No Abstract] [Full Text] [Related]
50. Varicella zoster exposure on paediatric wards between 2000 and 2007: safe and effective post-exposure prophylaxis with oral aciclovir.
Shinjoh M; Takahashi T
J Hosp Infect; 2009 Jun; 72(2):163-8. PubMed ID: 19282055
[TBL] [Abstract][Full Text] [Related]
51. Diagnosis, antiviral therapy, and prophylaxis of varicella-zoster virus infections.
Sauerbrei A
Eur J Clin Microbiol Infect Dis; 2016 May; 35(5):723-34. PubMed ID: 26873382
[TBL] [Abstract][Full Text] [Related]
52. Clinical and subclinical reactivations of varicella-zoster virus in immunocompromised patients.
Ljungman P; Lönnqvist B; Gahrton G; Ringdén O; Sundqvist VA; Wahren B
J Infect Dis; 1986 May; 153(5):840-7. PubMed ID: 3009635
[TBL] [Abstract][Full Text] [Related]
53. Oral acyclovir in immunocompetent patients with varicella.
Croze SM; Stoukides CA
Ann Pharmacother; 1994 Feb; 28(2):208-9. PubMed ID: 8173138
[No Abstract] [Full Text] [Related]
54. [Acyclovir-resistance zona in a immunocompromised HIV seronegative patient].
Lesueur A; Fillet AM; Bouscary D; Ginsburg C; Palmer P; Chaine B; Salmon-Ceron D; Dreyfus F; Huraux JM; Sicard D
Ann Dermatol Venereol; 1998 Feb; 125(2):127-8. PubMed ID: 9747231
[TBL] [Abstract][Full Text] [Related]
55. [Varicella-zoster infection--extreme clinical aspects].
Maniciuc C; Dorobaţ C; Hurmuzache M; Mihalache D; Luca V
Rev Med Chir Soc Med Nat Iasi; 2006; 110(4):852-5. PubMed ID: 17438887
[TBL] [Abstract][Full Text] [Related]
56. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
König C; Kleber M; Reinhardt H; Knop S; Wäsch R; Engelhardt M
Ann Hematol; 2014 Mar; 93(3):479-84. PubMed ID: 24318541
[TBL] [Abstract][Full Text] [Related]
57. [Antiviral therapy of immunocompromised patients].
Eggers HJ
Immun Infekt; 1984 Aug; 12(4):187-91. PubMed ID: 6090308
[TBL] [Abstract][Full Text] [Related]
58. Acyclovir treatment of varicella in otherwise healthy adolescents. The Collaborative Acyclovir Varicella Study Group.
Balfour HH; Rotbart HA; Feldman S; Dunkle LM; Feder HM; Prober CG; Hayden GF; Steinberg S; Whitley RJ; Goldberg L
J Pediatr; 1992 Apr; 120(4 Pt 1):627-33. PubMed ID: 1313098
[TBL] [Abstract][Full Text] [Related]
59. Varicella-zoster virus infection. The complex prevention-treatment picture.
Brody MB; Moyer D
Postgrad Med; 1997 Jul; 102(1):187-90, 192-4. PubMed ID: 9224486
[TBL] [Abstract][Full Text] [Related]
60. Low induction of varicella-zoster virus-specific secretory IgA antibody after vaccination.
Terada K; Niizuma T; Yagi Y; Miyashima H; Kataoka N; Sadahiro T
J Med Virol; 2000 Sep; 62(1):46-51. PubMed ID: 10935988
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
